Assessment of HPV 16 and HPV 18 antibody responses by pseudovirus neutralization, Merck cLIA and Merck total IgG LIA immunoassays in a reduced dosage quadrivalent HPV vaccine trial

Vaccine

Volumn 32, Issue 5, 2014, Pages 624-630

  Krajden, Mel ^a,b   Cook, Darrel ^a   Yu, Amanda ^a   Chow, Ron ^c   Su, Qiang ^c   Mei, Wendy ^c   McNeil, Shelly ^d   Money, Deborah ^b   Dionne, Marc ^e   Palefsky, Joel ^f   Karunakaran, Karuna ^a   Kollmann, Tobias ^b,g   Ogilvie, Gina ^a,b   Petric, Martin ^a,b   Dobson, Simon ^b,g  

^a BRITISH COLUMBIA CENTRE FOR DISEASE CONTROL   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c PROVINCIAL HEALTH SERVICES AUTHORITY   (Canada)

^d DALHOUSIE UNIVERSITY   (Canada)

^e LAVAL UNIVERSITY   (Canada)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g BC CHILDREN S HOSPITAL   (Canada)

Author keywords

Antibody response; HPV vaccine; Merck cLIA; Merck total IgG LIA; Pseudovirus neutralization

Indexed keywords

IMMUNOGLOBULIN G; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; VIRUS ANTIBODY; WART VIRUS ANTIBODY; WART VIRUS VACCINE;

ADOLESCENT; ADULT; ANTIBODY DETECTION; ANTIBODY RESPONSE; ARTICLE; CHEMILUMINESCENCE IMMUNOASSAY; CHILD; CLINICAL ASSESSMENT; COMPETITIVE LUMINEX IMMUNOASSAY; CONTROLLED STUDY; DRUG DOSE REDUCTION; FEMALE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; IMMUNOASSAY; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NEUTRALIZING ANTIBODY ASSAY; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; TOTAL IMMUNOGLOBULIN G IMMUNOASSAY; VACCINATION; VIRUS NEUTRALIZATION; YOUNG ADULT;

100% NEUTRALIZATION ENDPOINT; 90% NEUTRALIZATION ENDPOINT; ANTIBODY RESPONSE; CLIA; EIA; ENZYME IMMUNOASSAY; GEOMETRIC MEAN TITRE; GMT; HPV VACCINE; MERCK CLIA; MERCK COMPETITIVE LUMINEX IMMUNOASSAY; MERCK TOTAL IGG LIA; MERCK TOTAL IGG LUMINEX IMMUNOASSAY; MILLI-MERCK UNITS; MMU; NT(100); NT(90); NT(PARTIAL); PARTIAL NEUTRALIZATION ENDPOINT; PSEUDOVIRUS NEUTRALIZATION; PSEUDOVIRUS NEUTRALIZING ANTIBODY; PSV NAB; Q-HPV; QUADRIVALENT HPV; RED FLUORESCENT PROTEIN; RFP; TIGG; VIRUS-LIKE PARTICLE; VLP;

ADOLESCENT; ADULT; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CHILD; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; IMMUNIZATION SCHEDULE; IMMUNOASSAY; NEUTRALIZATION TESTS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; SENSITIVITY AND SPECIFICITY; YOUNG ADULT;

EID: 84891664236     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.09.007     Document Type: Article

References (27)

1. Einstein M. Acquired immune response to oncogenic human papillomavirus associated with prophylactic cervical cancer vaccines. Cancer Immunol Immunother 2008, 57:443-451.
2. World Health Organization Guidelines to assure the quality, safety and efficacy of recombinant human papillomavirus-like particle vaccines 2006, Expert Committee on Biological Standardization, Geneva, http://www.who.int/biologicals/publications/trs/areas/vaccines/human_papillomavirus/HPVg%20Final%20BS%202050%20.pdf [accessed 08.03.13].
3. Opalka D., Lachman C.E., MacMullen S.A., Jansen K.U., Smith J.F., Chirmule N., et al. Simultaneous quantitation of antibodies to neutralizing epitopes on virus-like particles for human papillomavirus types 6, 11, 16, and 18 by a multiplexed luminex assay. Clin Diagn Lab Immunol 2003, 10:108-115.
4. Villa L.L., Ault K.A., Giuliano A.R., Costa R.L.R., Petta C.A., Andrade R.P., et al. Immunologic responses following administration of a vaccine targeting human papillomavirus types 6, 11, 16, and 18. Vaccine 2006, 24:5571-5583.
5. Joura E.A., Kjaer S.K., Wheeler C.M., Sigurdsson K., Iversen O.-E., Hernandez-Avila M., et al. HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine. Vaccine 2008, 26:6844-6851.
6. Frazer I.H. Measuring serum antibody to human papillomavirus following infection or vaccination. Gynecol Oncol 2010, 118:S8-S11.
7. Stanley M.A. Epithelial cell responses to infection with human papillomavirus. Clin Microbiol Rev 2012, 25:215-222.
8. Opalka D., Matys K., Bojczuk P., Green T., Gesser R., Saah A., et al. Multiplexed serologic assay for nine anogenital human papillomavirus types. Clin Vaccine Immunol 2010, 17:818-827.
9. Pastrana D.V., Buck C.B., Pang Y.-Y.S., Thompson C.D., Castle P.E., FitzGerald P.C., et al. Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18. Virology 2004, 321:205-216.
10. Krajden M., Karunakaran K., So S., Palefsky J.M., Sharma R., Cook D., et al. Prevalence of human papillomavirus 16 and 18 neutralizing antibodies in prenatal women in British Columbia. Clin Vaccine Immunol 2009, 16:1840-1843.
11. Krajden M., Cook D., Yu A., Chow R., Mei W., McNeil S., et al. Human papillomavirus 16 (HPV 16) and HPV 18 antibody responses measured by pseudovirus neutralization and competitive Luminex assays in a two- versus three-dose HPV vaccine trial. Clin Vaccine Immunol 2011, 18:418-423.
12. Dobson S.R.M., McNeil S., Dionne M., Dawar M., Ogilvie G., Krajden M., et al. Immunogenicity of 2 doses of human papillomavirus vaccine in younger adolescents versus 3 doses in young women. JAMA 2013, 309:1793-1802.
13. Dias D., Van Doren J., Schlottmann S., Kelly S., Puchalski D., Ruiz W., et al. Optimization and validation of a multiplexed Luminex assay to quantify antibodies to neutralizing epitopes on human papillomaviruses 6, 11, 16, and 18. Clin Diagn Lab Immunol 2005, 12:959-969.
14. Walker G.A. Common statistical methods for clinical research with SAS examples 2002, SAS Institute Inc., Cary, NC. 2nd ed.
15. Brown D.R., Garland S.M., Ferris D.G., Joura E., Steben M., James M., et al. The humoral response to Gardasil over four years as defined by total IgG and competitive Luminex immunoassay. Hum Vaccin 2011, 7:230-238.
16. Roberts C., Swoyer R., Bryan J. Evaluation of the HPV 18 antibody response in Gardasil vaccinees after 48 months using a pseudovirus neutralization assay. Hum Vaccin Immunother 2012, 8:1-4.
17. Hernandez B.Y., Ton T., Shvetsov Y.B., Goodman M.T., Zhu X. Human papillomavirus (HPV) L1 and L1-L2 virus-like particle-based multiplex assays for measurement of HPV virion antibodies. Clin Vaccine Immunol 2012, 19:1348-1352.
18. Giuliano A.R., Lazcano-Ponce E., Villa L., Nolan T., Marchant C., Radley D., et al. Impact of baseline covariates on the Immunogenicity of a quadrivalent (types 6, 11, 16, and 18) human papillomavirus virus-like-particle vaccine. J Infect Dis 2007, 196:1153-1162.
19. Handisurya A., Day P.M., Thompson C.D., Buck C.B., Kwak K., Roden R.B.S., et al. Murine skin and vaginal mucosa are similarly susceptible to infection by pseudovirions of different papillomavirus classifications and species. Virology 2012, 433:385-394.
20. ® human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years. Hum Vaccin 2009, 5:705-719.
21. Longet S., Schiller J.T., Bobst M., Jichlinski P., Nardelli-Haefliger D. A murine genital-challenge model is a sensitive measure of protective antibodies against human papillomavirus infection. J Virol 2011, 85:13253-13259.
22. Ngan H.Y., Cheung A.N., Tam K., Chan K.K., Tang H., Bi D., et al. Human papillomavirus-16/18 ASO4-adjuvanted cervical cancer vaccine: immunogenicity and safety in healthy Chinese women from Hong Kong. Hong Kong Med J 2010, 16:171-179.
23. Faust H., Jelen M.M., Poljak M., Klavs I., Ucakar V., Dillner J. Serum antibodies to human papillomavirus (HPV) pseudovirions correlate with natural infection for 13 genital HPV types. J Clin Virol 2013, 46:336-341.
24. Antonsson A. Review: antibodies to cutaneous human papillomaviruses. J Med Virol 2012, 84:814-822.
25. Safaeian M., Ghosh A., Porras C., Lin S.-W., Rodriguez A.C., Schiffman M., et al. Direct comparison of HPV16 serological assays used to define HPV-naive women in HPV vaccine trials. Cancer Epidemiol Biomarkers Prev 2012, 21:1547-1554.
26. Ferguson M., Heath A., Johnes S., Pagliusi S., Dillner J. Results of the first WHO international collaborative study on the standardization of the detection of antibodies to human papillomaviruses. Int J Cancer 2006, 118:1508-1514. Collaborative Study Participants.
27. Bissett S.L., Wilkinson D., Tettmar K.I., Jones N., Stanford E., Panicker G., et al. Human papillomavirus antibody reference reagents for use in postvaccination surveillance serology. Clin Vaccin Immunol 2012, 19:449-451.